Lab study of Zn-DDC with myeloma drugs in multiple myeloma cells
Studies how myeloma cells respond to Zn-DDC, alone or with lenalidomide or pomalidomide.
Key facts
- Who runs it
- The Royal Wolverhampton Hospitals NHS Trust
- Where
- Wolverhampton, United KingdomSee the site
- Trial code
- Registry title
- Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
- Status
- Recruiting
- People taking part
- 70 people, planned
- Started
- 22 Oct 2021
- Expected to end
- Dec 2027
- Type of study
- Observational, 3 groups
- Treatments tested
- Zn-DDC
- Lanalidomide with Zn-DDC
- Pomalidomide with Zn-DDC
- Record updated
- 9 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a blood cancer, either myeloma or acute leukaemia, who can give informed consent.
- Age
- 18 years or over
- Sex
- All sexes can join.
- Disease stage
- Diagnosed with a blood cancer (haematological malignancy): either myeloma or acute leukaemia.
Main reasons for not taking part
- Pregnant patients cannot join.
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients diagnosed with haematological malignancy - either myeloma or acute leukaemia
- Patients must be 18 years or over
- Patients must be willing and able to give informed consent
Who cannot take part
- Pregnant patients will not be entered
Where in United Kingdom
- The Royal Wolverhampton NHS TrustWolverhampton, United KingdomContact: Supratik BasuTaking people
About the trial
What the trial wants to find out
The outlook for patients with haematological malignancies remains challenging. It has been shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as Imuthiol is highly toxic to cancer stem cells. Imuthiol has been intravenously used in clinical trials with an excellent safety record. Recent novel therapy and immunotherapy in haematological malignancies have improved outcome and survival but come with an increasing cost burden. Imuthiol could be an ideal affordable drug to study on it's own as well as in combination with other drugs in myeloma and other haematological malignancies. This may lead to potential combination therapies which will be very effective as well as affordable in the future. There is the need to look to see if this drug, Imuthiol and along with complementary drugs lenalidomide (Revlimid) and pomalidomide (Pomalyst) can help in haematological malignancy treatment. In order to do this there is the need to see how the cancer cells respond to the drugs in the laboratory before being able to trial the drug (or combination of drugs) out for treatment. The success of this study may lead to quick translation of Imuthiol into haematological malignancy treatment.
The 3 groups in the trial
- Zn-DDC
samples to be exposed with Zn-DDC (Imuthiol) alone
- Lenalidomide with Zn-DDC
samples to be exposed with Lenalidomide in combination with Zn-DDC
Treatment: Lanalidomide with Zn-DDC
- Pomalidomide with Zn-DDC
samples to be exposed with Pomalidomide in combination with Zn-DDC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway and Improve the Treatment Outcomes of Haematological Malignancies - A Translation Bench Study
- Plain-language title
- Lab study of Zn-DDC with myeloma drugs in multiple myeloma cellsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 April 2026